content of reactive oxygen and nitrogen species and of arginase-all of which are documented to contribute to MDS cell-mediated immunosuppression. Moreover, a peptide antagonist of the C5a receptor enhanced CD8+ T-cell antitumor responses and was as effective as the chemotherapeutic paclitaxel (Taxol) in retarding tumor growth.
Although MDS cells were originally observed in cancer patients and experimental animals >30 years ago, their role as spoilers of anti-tumor immunity is only now being appreciated. A heterogenous population of normal myeloid cells trapped in intermediate stages of differentiation, MDS cells accumulate in the blood, lymph nodes and at tumor sites in virtually all cancer patients. In healthy individuals, these cells differentiate into macrophages, dendritic cells and neutrophils, but tumors secrete a range of factors that disrupt normal differentiation of immune progenitor cells. MDS cells promote tumor growth by preventing the activation of CD4 + and CD8 + T lymphocytes, inhibiting natural-killercell cytotoxicity, stimulating tumorigenic cytokine production and increasing angiogenesis. Because MDS cells promote tumor growth through so many mechanisms, their elimination or inactivation should remove numerous barriers that interfere with cancer immunotherapies.
Cancer and complement
Suzanne Ostrand-Rosenberg Complement is a collection of serum proteins that are integral to inflammatory processes and to innate immune responses to infection. C5a, also known as anaphylatoxin, is generated from C5 by C5 convertase, which includes C3a, a cleavage product of C3 (Fig. 1) . Both C5a and C3a are chemoattractants and pro-inflammatory mediators. Based on epidemiological and experimental data linking chronic inflammation with tumor onset and progression 2 , Markiewski et al. 1 hypothesized that the inflammatory effects of complement may actually protect established tumors and enhance their growth. Using a murine model of cervical cancer and mice deficient in various complement components, they confirmed this hypothesis, showing that C5a deposited in the tumor vasculature attracts MDS cells, which express receptors for C5a, and boosts the potency of these cells by increasing their 
